Cancers (Nov 2022)

Research Progress for Targeting Deubiquitinases in Gastric Cancers

  • Tao An,
  • Yanting Lu,
  • Zhaoqi Gong,
  • Yongtao Wang,
  • Chen Su,
  • Guimei Tang,
  • Jingjing Hou

DOI
https://doi.org/10.3390/cancers14235831
Journal volume & issue
Vol. 14, no. 23
p. 5831

Abstract

Read online

Gastric cancers (GCs) are malignant tumors with a high incidence that threaten global public health. Despite advances in GC diagnosis and treatment, the prognosis remains poor. Therefore, the mechanisms underlying GC progression need to be identified to develop prognostic biomarkers and therapeutic targets. Ubiquitination, a post-translational modification that regulates the stability, activity, localization, and interactions of target proteins, can be reversed by deubiquitinases (DUBs), which can remove ubiquitin monomers or polymers from modified proteins. The dysfunction of DUBs has been closely linked to tumorigenesis in various cancer types, and targeting certain DUBs may provide a potential option for cancer therapy. Multiple DUBs have been demonstrated to function as oncogenes or tumor suppressors in GC. In this review, we summarize the DUBs involved in GC and their associated upstream regulation and downstream mechanisms and present the benefits of targeting DUBs for GC treatment, which could provide new insights for GC diagnosis and therapy.

Keywords